8-K: Alphatec Holdings Reports Strong 2023 Revenue Growth and Positive Outlook for 2024

Alphatec Holdings announced a 37% increase in full-year 2023 revenue to $482 million and projects continued growth with a revenue target of $595 million for 2024.

Summary

• Alphatec Holdings reported a 37% increase in total revenue for 2023, reaching $482 million.
• The company's adjusted EBITDA margin improved by approximately 890 basis points in 2023.
• For 2024, Alphatec anticipates total revenue to be around $595 million, with surgical revenue of $530 million and EOS revenue of $65 million.
• The company expects a 560 basis points improvement in adjusted EBITDA margin for 2024, with adjusted EBITDA projected to be approximately $22 million.
• The company updated its non-GAAP financial measures to include the non-cash impact of excess and obsolete inventory in the cost of goods sold.
• In the fourth quarter of 2023, surgical revenue grew by 34%, with volume growth accelerating to 29%.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved profitability metrics, and optimistic future guidance. However, the company is still reporting a net loss and has high operating expenses, which tempers the overall sentiment.

Positives

• The company experienced significant revenue growth in 2023, with a 37% increase year-over-year.
• There was a substantial improvement in adjusted EBITDA margin in 2023, indicating increased profitability.
• The company is projecting continued revenue growth in 2024, with a target of $595 million.
• The company is expanding its product portfolio with the launch of 15 new products and line extensions.
• The company is increasing its user base with a 27% increase in surgeon users compared to 2022.

Negatives

• The company reported a GAAP net loss of $187 million for the full year 2023.
• The company's operating expenses were $484 million for the full year 2023, exceeding total revenue.
• The company's non-GAAP adjusted EBITDA was negative $9 million for the full year 2023 under the updated definition.

Risks

• The company faces risks related to the development and commercialization of new products.
• There are uncertainties regarding the company's ability to execute its strategic operating plan.
• The company's future financial performance is subject to various factors, including market conditions and competition.
• The company's ability to achieve profitability is not guaranteed.
• The company is subject to risks related to litigation and intellectual property.

Future Outlook

The company expects total revenue for 2024 to approximate $595 million, with a 560 basis points improvement in adjusted EBITDA margin, and adjusted EBITDA of approximately $22 million.

Management Comments

• Pat Miles, Chairman and Chief Executive Officer, stated that ATEC's lateral sophistication is capable of building a good, profitable company, but they aspire for much more.
• Pat Miles also mentioned that they are building a spine monster, and the informatics and procedural innovation will further their mission to revolutionize spine care.
• Pat Miles said that they are all systems go in the pursuit of ATEC's best, which is yet to come.

Industry Context

The announcement reflects a positive trend in the medical device industry, particularly in the spine surgery sector, where innovation and procedural advancements are key drivers of growth. The company's focus on a comprehensive portfolio and surgeon training aligns with industry best practices.

Comparison to Industry Standards

• While specific competitor data is not provided, a 37% revenue growth is strong compared to the average growth rates of established medical device companies, which typically range from single-digit to low double-digit percentages.
• The company's focus on lateral approaches and procedural sophistication is in line with current trends in spine surgery, where minimally invasive techniques are gaining popularity.
• The company's adjusted EBITDA margin improvement of 890 basis points is a significant achievement, suggesting improved operational efficiency and cost management.
• The company's projected 23% revenue growth for 2024 is ambitious and would position them as a high-growth player in the spine surgery market if achieved.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and improved profitability metrics.
• Employees may be motivated by the company's positive performance and growth prospects.
• Customers (surgeons) will benefit from the company's innovative products and training programs.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower credit risk due to its improved financial performance.

Next Steps

• The company will continue to focus on product development and commercialization.
• The company will host a live webcast to discuss the financial results.
• The company will continue to train surgeons on its products and procedures.

Key Dates

Keywords

spine surgery, medical devices, revenue growth, EBITDA, surgical revenue, product launch, financial results, non-GAAP, Alphatec, ATEC